ANI Pharmaceuticals Inc (ANIP)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 19,872 | -62,665 | -56,058 | -25,962 | 3,157 |
| Revenue | US$ in thousands | 454,334 | 287,962 | 202,731 | 198,984 | 206,547 |
| Pretax margin | 4.37% | -21.76% | -27.65% | -13.05% | 1.53% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $19,872K ÷ $454,334K
= 4.37%
The pretax margin of ANI Pharmaceuticals Inc has exhibited variability over the past five years, ranging from -25.94% in December 2021 to 4.08% in December 2023. The negative pretax margins in 2021, 2022, and 2020 indicate that the company's pre-tax earnings were insufficient to cover its operating expenses and interest payments during those periods. However, the positive pretax margin of 4.08% in 2023 suggests an improvement in the company's profitability, indicating that it generated earnings before taxes that accounted for 4.08% of its total revenue. This positive trend in the pretax margin in 2023 may indicate better cost management, revenue growth, or efficiency improvements within the company compared to the preceding years. It is important for stakeholders to monitor this metric to assess ANI Pharmaceuticals Inc's ability to generate profits before tax expenses relative to its total revenue.
Peer comparison
Dec 31, 2023